12 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3.
Abbott Bioresearch Center
Special ergolines efficiently inhibit the chemokine receptor CXCR3 in blood.
Novartis Institutes For Biomedical Research
II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonists.
Ligand Pharmaceuticals
Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.
Novartis Institutes For Biomedical Research
Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.
Glaxosmithkline
Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives.
Ucb Pharma
Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies.
Idorsia Pharmaceuticals
Identification and structure-activity relationships of 1-aryl-3-piperidin-4-yl-urea derivatives as CXCR3 receptor antagonists.
Ucb Pharma